German cancer biotech BioNTech raises a mammoth $325M in latest round, bringing total haul to $1.4B+
With seven clinical assets, a string of key partnerships with titans of the pharmaceutical industry and whispers about a potential IPO, German cancer drug developer BioNTech on Tuesday unveiled a herculean $325 million in an upsized round of financing, marking one of the largest single private funding rounds for a biotechnology company in European history.
“If you add all the bits and bobs we’ve collected through European grants in the early days through to the upfront from are collaborations when we signed them and series…funding, I think we’re just over $1.4 billion now in total capital flows to the company,” noted Sean Marett, BioNTech’s chief business and commercial officer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,500+ biopharma pros reading Endpoints daily — and it's free.